Vor Biopharma Stock News

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inv

The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve

Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPCs) enabling new therapeutic approaches following t

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in three upcoming investor conferences:

Vor Biopharma Inc. (NASDAQ:VOR) price on Friday, February 11, fall -7.03% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.60. A look at the stock’s price movement, the close in the last trading session was $9.25, moving within a range at $8.35 and $9.65. Turning to its … Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think Read More »

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor's President and Chief Ex

Vor Biopharma Inc (VOR) shares closed today at 1.1% above its 52 week low of $10.46, giving the company a market cap of $394M. The stock is currently down 9.0% year-to-date, down 71.8% over the past 12 months, and down 71.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 17.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 7.5% lower than its 5-day moving average, 13.3% lower than its 20-day moving average, and 26.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 968.1% The company's stock price performance over the past 12 months lags the peer average by 140.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will b

Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of Buy from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective []

Vor Biopharma (NYSE:VOR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. []

Parametric Portfolio Associates LLC bought a new position in Vor Biopharma Inc. (NYSE:VOR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 85,631 shares of the companys stock, valued at approximately $1,597,000. Parametric Portfolio Associates LLC owned about 0.23% of Vor Biopharma as of its most []